PharmaEssentia Corp Sustainability Reports
A global biopharmaceutical company focused on the research, development, and manufacturing of therapeutic biologics. It specializes in treatments for myeloproliferative neoplasms and rare blood disorders, including its flagship approved interferon product, BESREMi.
Sector: Manufacturing
Country: Taiwan
Exchange: Taiwan Stock Exchange
LEI: 54930001GNQLDIFASK68
FIGI: BBG0063GF1X2
13 reports from 2019 to 2025
